The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies show variant antigen binding.

Skinny HSIL of the Cervix: Detecting a Variant of Excessive-grade Squamous Intraepithelial Lesions With a p16INK4a Antibody.
An antibody to p16INK4A acknowledges a modified type of galectin-3.
Using recombinant pseudotype virus-like particles harbouring inserted goal antigen to generate antibodies towards mobile marker p16INK4A.
P16INK4A |
|||
MO47002 | Neuromics | 100 ul | EUR 292.8 |
p16INK4A Conjugated Antibody |
|||
C48843 | SAB | 100ul | EUR 476.4 |
CDKN2A/p16INK4a Antibody |
|||
AF5484 | Affbiotech | 200ul | EUR 420 |
CDKN2A/p16INK4a Antibody |
|||
AF6667 | Affbiotech | 100ul | EUR 420 |
CDKN2A/p16INK4a Antibody |
|||
AF6898 | Affbiotech | 100ul | EUR 420 |
CDKN2A/p16INK4a Antibody |
|||
AF0228 | Affbiotech | 200ul | EUR 420 |
Anti-P16INK4a antibody |
|||
STJ180203 | St John's Laboratory | 0.1 ml | EUR 254.4 |
Anti-P16INK4a antibody |
|||
STJ180271 | St John's Laboratory | 0.1 ml | EUR 258 |
Anti-P16INK4a antibody |
|||
STJ180410 | St John's Laboratory | 0.1 ml | EUR 254.4 |
p16INK4a Antibody / CDKN2A |
|||
F54356-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
p16INK4a Antibody / CDKN2A |
|||
F54356-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
p16INK4a Antibody / CDKN2A |
|||
R20284-0.1ML | NSJ Bioreagents | 100ul | EUR 409 |
p16INK4a Antibody / CDKN2A |
|||
V8604-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: p16INK4a is a tumor suppressor protein. It is a specificinhibitor of cdk4/cdk6, and a tumorsuppressor involved inthe pathogenesis of a variety of malignancies. Recentanalyses of the p16INK4a gene revealed homozygousdeletions, nonsense, missense, or frameshift mutations inseveral human cancers. Although the frequency of p16INK4aabnormalities is higher in tumor derived cell lines than inunselected primary tumors, significant subsets of clinicalcases with aberrant p16INK4a gene have been reportedamong melanomas, gliomas, esophageal, pancreatic, lung,and urinary bladdercarcinomas, and some types of leukemia.Expression of p16INK4a (p16 positive) is highly correlatedwith human papilloma virus (HPV) infection in head and necksquamous cell carcinomas (HNSCC). p16 status is animportant prognostic indicator in HNSCC and the p16positive/HPV16 negative group is likely a distinct subgrouplacking any HPV genotype. |
p16INK4a Antibody / CDKN2A |
|||
V8604-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: p16INK4a is a tumor suppressor protein. It is a specificinhibitor of cdk4/cdk6, and a tumorsuppressor involved inthe pathogenesis of a variety of malignancies. Recentanalyses of the p16INK4a gene revealed homozygousdeletions, nonsense, missense, or frameshift mutations inseveral human cancers. Although the frequency of p16INK4aabnormalities is higher in tumor derived cell lines than inunselected primary tumors, significant subsets of clinicalcases with aberrant p16INK4a gene have been reportedamong melanomas, gliomas, esophageal, pancreatic, lung,and urinary bladdercarcinomas, and some types of leukemia.Expression of p16INK4a (p16 positive) is highly correlatedwith human papilloma virus (HPV) infection in head and necksquamous cell carcinomas (HNSCC). p16 status is animportant prognostic indicator in HNSCC and the p16positive/HPV16 negative group is likely a distinct subgrouplacking any HPV genotype. |
p16INK4a Antibody / CDKN2A |
|||
V8604SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: p16INK4a is a tumor suppressor protein. It is a specificinhibitor of cdk4/cdk6, and a tumorsuppressor involved inthe pathogenesis of a variety of malignancies. Recentanalyses of the p16INK4a gene revealed homozygousdeletions, nonsense, missense, or frameshift mutations inseveral human cancers. Although the frequency of p16INK4aabnormalities is higher in tumor derived cell lines than inunselected primary tumors, significant subsets of clinicalcases with aberrant p16INK4a gene have been reportedamong melanomas, gliomas, esophageal, pancreatic, lung,and urinary bladdercarcinomas, and some types of leukemia.Expression of p16INK4a (p16 positive) is highly correlatedwith human papilloma virus (HPV) infection in head and necksquamous cell carcinomas (HNSCC). p16 status is animportant prognostic indicator in HNSCC and the p16positive/HPV16 negative group is likely a distinct subgrouplacking any HPV genotype. |
p16INK4a Antibody / CDKN2A |
|||
V8694-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: p16INK4a is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype. |
p16INK4a Antibody / CDKN2A |
|||
V8694-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: p16INK4a is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype. |
p16INK4a Antibody / CDKN2A |
|||
V8694SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: p16INK4a is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype. |
CDKN2A / p16INK4a Polyclonal Antibody |
|||
27512-100ul | SAB | 100ul | EUR 302.4 |
CDKN2A / p16INK4a Polyclonal Antibody |
|||
27512-50ul | SAB | 50ul | EUR 224.4 |
CDKN2A / p16INK4a Polyclonal Antibody |
|||
27527-100ul | SAB | 100ul | EUR 302.4 |
CDKN2A / p16INK4a Polyclonal Antibody |
|||
27527-50ul | SAB | 50ul | EUR 224.4 |